|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, both RET/PTC1<sup>TG</sup>;Patz1<sup>+/-</sup> and RET/PTC1<sup>TG</sup>;Patz1<sup>-/-</sup> mice developed a more aggressive thyroid cancer phenotype-characterized by higher Ki-67 expression, presence of ATCs, and increased incidence of solid variants of PTC-than that shown by RET/PTC1<sup>TG</sup>; Patz1<sup>+/+</sup> compound mice.
|
29584698 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In papillary thyroid carcinoma (PTC), genetic events involve RET and TRK (rearrangements) and BRAF and RAS (mutations), although RAS mutations are uncommon except in the follicular variant of PTC.
|
17131411 |
2006 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
On the contrary, genetic alterations in sporadic papillary thyroid carcinoma (PTC) are better characterized, the most common one involving the activation of the proto-oncogene RET through somatic rearrangements.
|
11463498 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, we postulate that the correlation between the RET/PTC rearrangement type and the aggressiveness of human PTC is related to the efficiency with which the oncogene subtype delivers mitogenic signals to thyroid cells.
|
11786418 |
2002 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer.
|
25789503 |
2015 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further investigation is necessary to confirm a potential pathogenetic role of exon 13 and 14 RET mutations with regard to the development of PTC.
|
12193298 |
2002 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Similar results were obtained with rat sarcoma and RET/papillary thyroid cancer inhibitors.
|
23559083 |
2013 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-function mutations in the RET proto-oncogene resulting in a constitutively active receptor tyrosine kinase have been identified as responsible for three subtypes of multiple endocrine neoplasia type 2 (MEN-2) and the development of sporadic medullary and papillary thyroid carcinoma.
|
12869215 |
2003 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Preliminary results from our molecular oncology studies on adult-onset papillary thyroid cancer provide evidence for the induction of RET/PTC rearrangements and BRAF point mutation (both known to be early stage events in adult-onset papillary thyroid cancer) but with a difference: cases associated with the rearrangements were more frequent at high doses, and developed sooner than those with BRAF mutation.
|
18406659 |
2008 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data provide limited evidence that TSHR- and RET-related genes are related to papillary thyroid cancer risk.
|
17220349 |
2007 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.
|
8634704 |
1995 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Eighteen percent of post-Chernobyl PTC that exhibit RET rearrangements also showed chromosomal imbalances indicating that either additional genetic events are involved in this subset of tumors, or that intratumoral genetic heterogeneity exists in these tumors, suggesting a oligoclonal pattern to tumor development.
|
15650359 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To elucidate the role of these RET ligands in MTC tumorigenesis, their expression was determined in 15 MTC samples, one papillary thyroid carcinoma (PTC) and three normal thyroid tissue specimens.
|
10822229 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic background among races may contribute to the different frequencies of PTC/retTPC oncogene in thyroid papillary carcinoma.
|
8275421 |
1994 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
H4 has previously been implicated in pathogenesis of papillary thyroid carcinoma as a fusion partner of RET.
|
11389034 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CONCLUSIONS Expression of the BRAF V600E mutation and RET/PTC translocation promoted the activity of NF-κB, expression of inflammatory mediators, and lymph node metastases in patients with PTC.
|
30254191 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previous reports, from our and other laboratories, showed that post-Chernobyl papillary thyroid carcinomas are characterized by a high frequency (about 60%) of RET oncogenic rearrangements (Fugazzola et al., 1995; Klugbauer et al., 1995; Ito et al., 1994).
|
8806699 |
1996 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Several clones were isolated in which PDGFbetaR fused in frame to H4/D10S170, a previously described ubiquitously expressed gene that is fused to the ret protein tyrosine kinase to form the PTC-1 oncogene in approximately 20% of papillary thyroid carcinomas.
|
10910073 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcinoma (MTC and PTC) and cutaneous melanoma and to analyze BRAF(V600E) mutation in plasma and tissues.
|
24858900 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Eight PTCs expressed two different mutations (1 RET/PTC + BRAF, 6 NTRK1 + BRAF, 1 RET/PTC + NTRK1).
|
20640859 |
2010 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation.
|
21339735 |
2011 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma.
|
24510380 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
More than 90% of PTC with RET rearrangement exhibit a PTC1 or PTC3 type of rearrangement with an inversion of the H4 or ELE1 gene, respectively, on chromosome 10.
|
11318605 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutation of RET leads to the constitutive signal activation causing papillary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN2).
|
17555548 |
2007 |